Consumer drug advertising is favorite culprit in rising Rx costs

Share this article:

Consumer drug advertising remains corporate benefit managers' favorite culprit in rising prescription drug costs, according to an Arxcel survey. Forty-five percent cited DTC as the top cause of rising costs, compared to 36% in 2006 and 30% in 2005. R&D costs placed second, with 24%, and an aging population ranked third, at 17%. 

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.